Envoy Medical, Inc. (COCH) AI Stock Summary

Snapshot

Envoy Medical is a tiny, unprofitable medical device company burning through cash while waiting for regulatory approval. FY 2025 revenue was a mere $241K, dwarfed by a $23.8M net loss driven by $12.5M in R&D spending. The company has a $319M accumulated deficit and disclosed substantial doubt about its ability to continue as a going concern. A recent $30M capital raise boosted cash to $25.3M, extending the runway to roughly 12 months, but the stock faces immediate pressure from a Nasdaq delisting notice and significant share dilution from the financing.

What's Happening Right Now

• Sat 23rd May '26 · Delisting Risk: Nasdaq confirmed Envoy Medical failed to meet the $1.00 minimum bid price requirement, granting a 180-day window to cure the deficiency, likely via a reverse stock split.
• Mon 11th May '26 · Clinical Milestone: The company completed enrollment of 56 patients in its pivotal trial for the fully implanted Acclaim cochlear implant and closed a $30M financing round.
• Thu 16th Apr '26 · Board Appointment: Envoy Medical appointed Chas McKhann, a veteran med-tech executive with a track record of successful exits, to its Board of Directors.

Ownership

Institutions hold 21.6% of the company, while insiders hold 2.7%.

Bottom Line

Envoy Medical is a high-risk binary bet on a single product. The business generates almost no revenue and loses millions of dollars every year, relying entirely on outside funding to stay alive. The recent $30M raise buys time, but the going-concern warning and Nasdaq delisting notice signal serious structural stress. The stock is near its 52-week high, pricing in optimism about the upcoming FDA submission, but the path to profitability is long and uncertain. This is not a stable investment; it is a speculative play on whether the Acclaim implant wins approval and sells well.